Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)
Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) was the recipient of some unusual options trading activity on Wednesday. Investors purchased 1,002 put options on the company. This is an increase of approximately 1,791% compared to the average volume of 53 put options.
马拉维生命科学控股公司(纳斯达克代码:MRVI-GET Rating)周三接受了一些不寻常的期权交易活动。投资者购买了该公司的1002份看跌期权。与53份看跌期权的平均成交量相比,这一数字增长了约1791%。
Maravai LifeSciences Price Performance
Maravai LifeSciences性价比
Shares of NASDAQ:MRVI opened at $14.01 on Thursday. The firm's 50 day moving average price is $14.12 and its 200-day moving average price is $20.26. Maravai LifeSciences has a twelve month low of $12.16 and a twelve month high of $41.82. The company has a quick ratio of 6.68, a current ratio of 7.22 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $3.58 billion, a PE ratio of 7.83 and a beta of -0.25.
周四,纳斯达克:MRVI的股价开盘报14.01美元。该公司的50日移动均线价格为14.12美元,200日移动均线价格为20.26美元。Maravai LifeSciences的12个月低点为12.16美元,12个月高位为41.82美元。该公司的速动比率为6.68,流动比率为7.22,债务权益比为0.62。该股市值为35.8亿美元,市盈率为7.83倍,贝塔系数为-0.25。
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last released its earnings results on Wednesday, November 2nd. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.32 by $0.05. Maravai LifeSciences had a net margin of 26.29% and a return on equity of 69.19%. The company had revenue of $191.26 million for the quarter, compared to analysts' expectations of $193.83 million. Equities research analysts expect that Maravai LifeSciences will post 1.79 EPS for the current year.
马拉威生命科学(纳斯达克:MRVI-GET Rating)上一次发布财报是在11月2日(周三)。该公司公布本季度每股收益为0.37美元,比分析师普遍预期的0.32美元高出0.05美元。Maravai LifeSciences的净利润率为26.29%,股本回报率为69.19%。该公司当季营收为1.9126亿美元,高于分析师预期的1.9383亿美元。股票研究分析师预计,Maravai LifeSciences本年度每股收益将达到1.79股。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Institutional Investors Weigh In On Maravai LifeSciences
机构投资者参与Maravai LifeSciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Captrust Financial Advisors raised its stake in Maravai LifeSciences by 1.3% during the 1st quarter. Captrust Financial Advisors now owns 33,535 shares of the company's stock worth $1,183,000 after acquiring an additional 442 shares during the period. Xponance Inc. raised its stake in Maravai LifeSciences by 5.3% during the 2nd quarter. Xponance Inc. now owns 12,838 shares of the company's stock worth $365,000 after acquiring an additional 641 shares during the period. Zions Bancorporation N.A. bought a new stake in Maravai LifeSciences during the 1st quarter worth approximately $28,000. ProShare Advisors LLC raised its stake in Maravai LifeSciences by 6.5% during the 3rd quarter. ProShare Advisors LLC now owns 12,804 shares of the company's stock worth $327,000 after acquiring an additional 785 shares during the period. Finally, Signaturefd LLC grew its holdings in Maravai LifeSciences by 200.5% during the 3rd quarter. Signaturefd LLC now owns 1,202 shares of the company's stock valued at $31,000 after buying an additional 802 shares in the last quarter. Institutional investors own 48.67% of the company's stock.
一些机构投资者和对冲基金最近增持或减持了该公司的股份。CapTrust Financial Advisors在第一季度将其在Maravai LifeSciences的持股增加了1.3%。CapTrust Financial Advisors在此期间额外购买了442股,现在拥有33,535股该公司股票,价值1,183,000美元。Xponance Inc.在第二季度增持了Maravai LifeSciences 5.3%的股份。Xponance Inc.在此期间增持了641股,目前持有12,838股该公司股票,价值36.5万美元。Zion Bancorporation N.A.在第一季度购买了Maravai LifeSciences的新股份,价值约2.8万美元。ProShare Advisors LLC在第三季度将其在Maravai LifeSciences的持股增加了6.5%。ProShare Advisors LLC在此期间额外收购了785股,现在拥有12,804股该公司股票,价值327,000美元。最后,Signaturefd LLC在第三季度增持了200.5%的马拉维生命科学股份。Signaturefd LLC现在拥有1,202股该公司股票,价值31,000美元,上个季度又购买了802股。机构投资者持有该公司48.67%的股份。
About Maravai LifeSciences
关于Maravai LifeSciences
(Get Rating)
(获取评级)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Maravai LifeSciences控股公司是一家生命科学公司,提供能够在美国和国际上开发药物疗法、诊断、新型疫苗和支持人类疾病研究的产品。该公司的产品涉及生物制药开发的关键阶段,包括用于诊断和治疗应用的核酸、在生物制药产品生产过程中检测杂质的基于抗体的产品,以及检测各种组织中蛋白质表达的产品。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Maravai LifeSciences (MRVI)
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
- 2 Biotechs Making Waves With A Single Product in their Pipeline
- 免费获取StockNews.com关于Maravai LifeSciences(MRVI)的研究报告
- 好时为什么是一只甜蜜的衰退股票
- 亚马逊股票是否会在2023年为投资者提供服务?
- 分析师将货运情绪转回远期
- 各机构预订波音航班
- 两家生物技术公司在其流水线中以单一产品掀起波澜
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Maravai生命科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Maravai LifeSciences和相关公司的最新新闻和分析师评级的每日简要摘要。